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Henry Ford Hospital Clinicopathological Conference 
Metamorphosis in chronic granulocytic leukemia in a 60-year-old 
Participants: 
Pro toco l : Dr. Ellis J. Van Slyck, Depar tment of Internal Med ic ine , Div is ion of Hemato logy 
Discussant: Dr. Robert K. N i xon , Depar tment of Internal Med ic ine , Second Med ica l Div is ion 
Radio logy: Dr. Mark C. Weingarden, Depar tment of Diagnost ic Radiology 
Pathology: Dr. John W. Rebuck, Depar tment of Pathology, D iv is ion of Hemato logy 
man 
Case Presentation 
This 60-year-old white man came to Henry Ford Hospital in 
December 1975, complaining of increased fatigability over the 
preceding year. He had also noted mid-abdominal soreness after 
lifting. His own physician found that his spleen was grossly 
enlarged and that he had a high white blood count. His past 
history included a partial gastrectomy for an ulcer in 1960 and a 
stroke in 1972 with no residual. He was said to be diabetic since 
1973 and had been taking 12 units of insulin. 
On admission, the pertinent physical findings were blood pres-
sure 142/78, pulse 80 and regular. He was in no distress and 
mildly obese. There was no lymphadenopathy. Abdominal exam 
revealed a liver span of 10 cm. The spleen was markedly enlarged, 
measuring 16 cm below the left costal margin with a total span of 
24 cm. 
Initial laboratory values revealed a hemoglobin of 10.2 gms, white 
count 263,000/cu ml. The peripheral smear showed moderate 
polychromasia of RBCs. The WBC differential was as follows: 
segmented neutrophils 36%, bands 25%, metamyelocytes 6%, 
myelocytes 12%, early myelocytes 6%, myeloblasts 1 % , 
eosinophils 5% (3 immature), basophils 7% (immature). Phila-
delphia chromosome was present. LAP was 0. The platelet count 
was 637,000/cu ml. Reticulocyte count was 1.2%. Uric acid was 
8.7 mg/dl. The LDH was greater than 700 units and the tri-
glyceride was 345 mg/dl. BUN, creatinine, electrolytes, and 
alkaline phosphatase values were normal. The VDRL was non-
reactive. The PT and PTT were within normal limits. Urinalysis 
was normal. Vitamin B12 level was 7,616 pg/dl. Serum folic acid 
was 4.9 ng/dl. The bone marrow aspiration and biopsy were 
consistent with a diagnosis of chronic granulocytic leukemia 
(CCL). X-ray of the chest showed no acute process. The EKC was 
considered normal. 
The patient was placed on myleran and responded appropriately 
with a satisfactory reduction of his white cell count, restitution of 
his hemoglobin, and diminution of his spleen size. 
He continued this treatment until he was discharged on Decem-
ber 23, at which time the dose was reduced to 2 mgs three times 
a day. Wh i l e in the hospi tal , his insul in was d iscont inued. 
The patient was instructed in a diabetic diet and also given 
allopurinol. 
As an outpatient, his myleran dosage was gradually tapered as the 
blood counts responded. On February 27, the white count was 
40,000 and the platelet count 400,000. On May 10, the white 
count was 21,000, hemoglobin 13.6% gm, and the platelet count 
717,500. In July 1976, the white count was 28,400, hemoglobin 
13.8 gm%, and platelet count 620,000. In August, 1976, the 
patient was noted to have a white count of 62,000 and a platelet 
count of 1.2 mil l ion. The spleen, although smaller, was easily 
palpable. 
The patient was not seen again until June 1977, having been 
followed by his local doctor. At this time he reported that he had 
been hospitalized on several occasions for Gl bleeding and that x-
rays had demonstrated gastric and duodenal ulcerations. He had 
continued to take myleran more or less on a continuous basis. A 
dull, constant aching in the upper quadrant, weight loss, progres-
sive fatigue and some ankle edema had prompted his return to 
Henry Ford Hospital. On June 16,1977, his physical examination 
showed a blood pressure of 130/88. The pulse was 88 and regular. 
Pertinent findings were generalized hyperpigmentation, bilateral 
basilar rales, an unremarkable cardiac auscultation, a soft abdo-
men with splenomegaly 3-4 finger breadths below the level of the 
umbilicus. There was a small amount of pedal edema. The 
hemoglobin was 19.4 gm% and white count 78,300. The findings 
of hyperpigmentation and rales raise the question of interstitial 
pulmonary changes related to myleran therapy. 
After therapy with Rubidazone was started, the white count 
responded from 78,000 to 4,700. Hemoglobin at this point was 
8.4 gm%, and the platelet count was 195,000. On September 6, 
he had completed three courses of Rubidazone. His blood count 
was hemoglobin 7.4 gm%, white count 9,900. The nature of the 
blood and marrow differentials at this time changed dramatically 
and wi l l be the subject of the discussion and slide presentation. 
The patient's course was downhil l over the next two to three 
months with weakness, fever, diffuse bone aching, further en-
largement of the liver and spleen, more edema, bilateral calf 
tenderness, further progression of the anemia, and, subsequently, 
another marked increase in the white cells to over 200,000. 
The patient returned on September 30, weak, febrile, and aching 
in most of his bones. His temperature was 39.8, blood pressure 
85/60, and pulse rate was 92. His skin was dry and hot. Marked 
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hepatosplenomegaly was noted. There was 2 4- edema of the 
lower extremities and bilateral calf tenderness. There were a few 
basilar rales. The neck was supple. Pertinent laboratory data 
included a hemoglobin of 6.8 gm%, and a white count of 
280,000. The many bizarre forms in the peripheral blood pre-
cluded an accurate platelet count. 
The patient died on October 3, after he failed to respond to 
appropriate antibiotics forthe consolidated right upper lobe seen 
on x-ray Sputum culture had shown moderate E. coli. 
Our task is to try to define the possible complications this patient 
experienced as a result of his chronic granulocytic leukemia. 
Radiology Findings 
Dr. Weingarden: 
When the patient's first x-ray film (Fig. 1) was taken on 
December 15, the day after admission, we found no signifi-
cant abnormalities. This film shows some blunting at the 
right costophrenic angle, probably due to pleural thicken-
ing, but no acute process was seen at this time. Six months 
later, on June 16, 1977, he was examined again (Fig. 2). 
Bilateral densities involving the lung fields diffusely were 
noted, as well as a reticular nodular pattern of an interstitial 
nature. Dr. Nixon mentioned the possibility that the patient 
had myleran toxicity, and this is also possible from looking 
at this film. By the time of the patient's death on October 3, 
the consolidative changes in the right upper lobe had 
increased, although the left lung still seemed not to be 
involved (Fig. 3). The most likely radiographic diagnosis at 
this point would be a pneumonitis with some atelectasis of 
the right upper lobe. Also, the trachea may be shifted 
slightly to the right. 
Clinical Discussion 
Dr. Nixon: 
Our knowledge of the evolution of chronic granulocytic 
leukemia (CGL) has been greatly enhanced by the study of 
atomic bomb casualties at the University of Hiroshima. In 
the earliest proliferative phase, after the presence of a 
Philadelphia chromosome has been initially ascertained, 
there is approximately a 6.3 year proliferative period to the 
point where we can first discern a hematologic change at 
about a 10,000 white cell count, accompanied by the 
appearance of basophilia, increase in platelets, and a 
decrease in leukocyte alkaline phosphatase. At approxi-
mately 20,000 white cell count, immature granulocytes, 
less than 5%, begin to appear, and at a white cell count of 
25,000, an increase in serum vitamin B12 is detectable. 
When the white blood cells increase to between 50,000 
and 100,000, the clinical features, including splenomegaly, 
make the diagnosis evident. 
Fig. 1 
Fig. 2 
This patient responded satisfactorily to myleran therapy for 
five to six months and then underwent a decided change. 
Over the next three to four months, in spite of a change of 
chemotherapy, he continued to decline and died with a 
terminal infection. 
What are the possible things that may happen to a patient 
with chronic granulocytic leukemia and that would seem 
to pertain best to the patient under discussion? Myelosup-
pression and a lethal outcome from chemotherapy may 
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Fig. 3 
occur. There may be a transition to myelofibrosis, or non-
associated diseases may prevail, particularly those com-
mon to middle life, and these may be responsible for death 
before the final evolution of the leukemia. Most CGL 
patients (in the range of 70%) move into what is termed an 
accelerated phase, which terminates in a blast crisis. This 
transition is characterized by increasing anemia, increased 
leukocytosis, or cytopenia. Our patient, with increased 
fatigue, fever, bone pain, as well as further hematologic 
change occurring some five to six months after initial 
treatment w i th myleran, gave evidence that the basic 
course of his disease had markedly altered in a way com-
patible with the accelerated phase that precedes a blast 
crisis. In recent years, we have become aware that just as 
the Philadelphia chromosome involves not only gran-
ulocytes but erythroid elements, megakaryocytes, mono-
cytes and lymphocytes, so the blast transformation that 
inevitably occurs in practically all CGL patients may actu-
ally involve any ofthese cell lines. Recognition of a termi-
nal lymphoblastic change is clinically important because it 
demands a change in therapy, which may, for a period, be 
more effective. Measurement of a terminal transferase (de-
oxynucleotidyl transferase), a DNA polymerase, facilitates 
the diagnosis of this lymphoblastic type of crisis. 
At this point comments are in order about the unusual 
multiple duodenal and gastric ulcerations which occurred 
in our patient when his course was changing hemato-
logical ly. These alterations may have been a response to a 
marked histamine stimulus supplied by a basophilia which 
may accompany a blast crisis. Whether, in turn, this in-
crease in basophils was great enough to qualify for the 
diagnosis of basophilic leukemia would be speculative, but 
certainly of interest. Since the symptom expressions of 
histamine release in basophilic leukemia are not as pro-
found as one encounters with a mast cell origin of his-
tamine release, we may not have the other features that 
characterize systemic mastocytosis, such as a characteristic 
flush or other marked symptoms of hyperhistaminemia. 
The terminal event of a pneumonia that did not respond to 
antibiotics would be consistent with this man's disease. In 
the evolution of chronic granulocytic leukemia, functional 
changes in granulocytes presumably occur, as suggested by 
alterations in their phagocytic indices and bactericidal 
capacity; these, in turn, may make the patient more suscep-
tible to infection. 
Student Diagnosis: 
The medical students feel that the early clinical course is 
consistent with the diagnosis of CGL except for three 
observations: 1) the duration o f the disease was less than 
two years; 2) the elevated platelet count did not decrease 
with treatment comparable to the decrease in the patient's 
white count; and 3) the peripheral smear later in the 
patient's course had a number of bizarre forms which 
precluded an accurate platelet count. We feel that the 
hyperpigmentation and the bilateral basilar rales were 
probably secondary to the myleran therapy. We feel that 
the platelets are an abnormal and significant part of the 
picture, first, because of their increased number. Also, the 
thrombotic and hemorrhagic episodes of the patient's 
edema, the possible stomach infarct, and the bleeding from 
the ulcer all suggest abnormal platelet function, as do the 
bizarre platelet forms. Medical students here suspect that 
the patient has a megakaryocytic blast transformation of 
chronic granulocytic leukemia, which is an unusual condi-
tion occasionally seen as the terminal event in chronic 
granulocytic leukemia. 
Questions 
Are you making any educated guesses about the nature of 
this pneumonitis? Is it some unusual type of infection? 
What etiology do you suspect? 
Dr. Nixon: 
I think it is probably an ordinary bacterial pneumonia. I 
don't think we need to suspect some unusual organism, 
which certainly may occur in a variety of hemopoietic 
diseases and especially with immunosuppressive therapy. I 
am wil l ing to accept, at this stage of the man's disease, an 
ordinary bacterial process which didn't respond to antibi-
otics primarily because the patient had no defenses left to 
respond with. 
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In regard to the duration of the disease mentioned by the 
students, I would answer that from the time of diagnosis to 
the culmination o f the blast crisis the period is generally 
one to four years. 
Pathology Discussion 
Dr. Rebuck: 
I would like to add a point about the duration of chronic 
granulocyt ic leukemia. We should now consider two 
courses in a disease process: first, the natural evolution of 
the disease before treatment becomes available, and then, 
the course of the disease as modified by treatment. Pre-
viously, with radiotherapy alone, the median survival of a 
patient with CGL was 3.1 years. I believe the latest SWOG 
figu res with chemotherapy have a median survival just 
under that figure. Lest you think there has been no progress, 
the life quality of such patients has greatly improved, even 
though we have not increased their survival time. 
Well, Dr. Nixon, thank you for focusing on the real prob-
lem in this case, namely, the sudden change in the nature of 
our patient's course in June 1977. I liked your term the 
"accelerated phase". The term "-blast crisis" generally 
used in the U.S. to refer to such acceleration of the course 
of chronic granulocytic leukemia is not nearly as accurate. 
Gunz' standard text on the leukemias (1) prefers the term 
"metamorphosis." The reason I like "acceleration" or 
"metamorphos is " is that in CGL not all the dramatic 
changes are conversions to a -blast crisis, although I am 
glad you mentioned a most important conversion recently 
recognized, that of a truly lymphoblastic crisis, proved by 
demonstrating lymphoblastic surface markers on the -blasts 
of some cases. You also mentioned the common my-
eloblastic crisis or the conversion to an acute myelomono-
cytic leukemia and, rarely, to an acute erythroblast ic 
leukemia or acute megakaryocytic leukemia, as mentioned 
in the students' diagnosis. 
The nature o four patient's acceleration in June 1977 was 
none of the aforementioned, as study of his blood smear 
and bone marrow at the time indicated. Examination of the 
peripheral blood smear revealed a leukocytic differential 
count as follows: myeloblasts 8.5%; progranulocytes 
4.0%; neutrophilic promyelocytes 0.5%; neutrophilic my-
elocytes 3.0%; neutrophilic metamyelocytes 2.0%; bands 
3.0%; segmented neutrophils 21.5%; eosinophilic pro-
myelocytes 0 .5%; eosinophi l ic myelocytes 3.5%; 
eosinophilic metamyelocytes 1.0%; eosinophils 3.0%; im-
mature basophils 15.5% (Fig. 5); basophilic granulocytes 
26.0% (Fig. 4); lymphocytes 7.5%; and monocytes 0.5%. 
Some of the neutrophilic myelocytes had coarse, dark 
chromatin patterns, the so-called Pelgeroid appearance. In 
the leukocyte count, 2 megakaryocytic nuclei were en-
countered per 100 leukocytes, and 1 polychromatophilic 
normoblast per 100 leukocytes. The mature erythrocytes 
showed anisocytosis, target cells, burr cells, poikilocytosis, 
polychromasia, basophilic stippling, blister cells, and rare 
spherocytes. An occasional platelet was a giant monster in 
size and appearance, i.e., greater than 8 f im in diameter. 
Larger than normal platelets are often found as a sign of 
increased rates of platelet production, but the monster 
forms that appeared here are found only in the my-
eloproliferative syndromes, both in chronic granulocytic 
leukemia as well as in agnogenic myeloid metaplasia. 
Indeed, increased basophilic granulocytes may be found in 
both CGL and agnogenic myeloid metaplasia. However, 
such greatly increased numbers and degree of basophil 
immaturity as found in this patient are a feature only of 
granulocytic leukemia and its basophilic variants to be 
discussed below. 
When Paul Ehrlich was a medical student, he used the 
aniline dyes to discover the tissue mast cell and the pecu-
liar property of the mast cell granule to change the dye 
color, a property he termed "metachromasia". This was in 
1877. Fourteen years later, long after delineating the neu-
trophilic, eosinophilic and normoblastic and megaloblastic 
series we know today, he worked out the basophilic gran-
ulocytic development in a case of CGL. The basophilic 
series developed in a fashion parallel to the previously 
described neutrophilic and eosinophilic series and was 
similarly derived from the marrow stem cells. The first 
member of the series he named "basoph i l i c pro-
myelocyte," for the member with the first appearance of 
metachromat ical ly staining specif ic granules. The 
mitotically dividing offspring he designated "basophilic 
myelocytes," which transformed in turn without further 
cell division to the "basophilic metamyelocyte," with its 
broadly indented nucleus, and to the end-stage, mature 
"basophilic granulocyte" with its poorly segmented, but 
irregularly lobulated nucleus. 
Had we performed the differential only on the predominant 
basophilic granulocytic series, the basophilic leukocytic 
di f ferent ia l revealed basophi l ic promyelocytes 5%; 
basophilic myelocytes 14%; basophilic metamyelocytes 
11%; and basophilic leukocytes 70%. Amid the 5% imma-
ture eosinophils in the general differential, we ran across 
some of the eosinophilic promyelocytes and myelocytes 
which contained large, refractile, globular, second set lyso-
somes with both eosinophilic staining in some areas of the 
cell body intermingled with basophilic staining, similarly 
structured granules. Ehrlich noted such eosinophilic gran-
ulation and correctly gave no great significance in cell 
identification to such members of the eosinophilic series. 
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From time to time, they are misinterpreted as signifying a 
leukemic change per se, which they do not. 
From the examination of the peripheral blood slide we 
diagnosed a "basophilic leukemic conversion" of CGL and 
not exactly a " -b las t cr is is , " as had been expected 
clinically. After all, the granulocytic stem cells comprised 
only 13.5% in the blood slide. To support our interpretation 
of the peripheral blood, we next examined the bone mar-
row aspirate at this time. This revealed myeloblasts 13.0%; 
progran ulocytes 4.0%; neutrophilic promyelocytes 3.4%; 
neutrophi l ic myelocytes 0 .4%; neutrophi l ic meta-
myelocytes 2.2%; bands 0.6%; segmented neutrophils 
13.6%; eosinophilic promyelocytes 2.2%; eosinophilic 
myelocytes 1.8%; eosinophilic metamyelocytes 1.2%; 
eosinophils 4.8%; immature basophils 14.6%; basophilic 
granulocytes 28% (Figs. 4 and 5); lymphocytes 6.2%; 
monocytes 0.2%; megakaryoblasts 2.4%; polychroma-
tophilic normoblasts 0.8%; orthochromatic normoblasts 
0.4%; normoblastic mitoses 0.2%. Some ofthe myeloblasts 
were micromyeloblasts supporting the leukemic nature of 
the process. Putting the marrow findings together with 
those from the blood slide, we made a diagnosis of "sub-
acute basophilic leukemia" complicating CGL, which Dr. 
Nixon discussed as one possibility. An earlier biopsy of the 
patient's marrow in April 1977, which had been obtained 
elsewhere, was made available to us, and a surprising 
fibrosis of the entire marrow spaces, highlighted only by 
the presence of entrapped megakaryocytes, intervened at 
that time. The intervention of marrow fibrosis in a known 
case of CGL often signifies a severe prognosis, as in this 
case. 
As stated above, Ehrlich himself, as early as 1891, had 
noted moderate but significant increases in basophilic 
granulocytes in CGL. In 1906 Joachim (3) was the first to 
report a variant of CGL such as we see in our study with 
extreme basophilia. From that time on, sporadic cases of 
CGL (3-9) with extreme elevation in the basophilic leuko-
cyte count have been reported with the designation of 
"basophilic leukemia." Forkner, in his 1938 pioneer text on 
leukemia (3), included a chapter on basophilic leukemia 
and was able to cite 11 cases in this category. Forkner (3) 
suggested that "many if not all of the cases recorded of 
basophilic leukemia in man may represent merely an exag-
geration of the basophilia seen not infrequently in patients 
with straightforward chronic myelogenous leukemia par-
ticularly subsequent to treatment." This early view has 
been confirmed in most respects by more recent reviews 
(1). 
Why, then, our conference case? First of all, one can verify 
the existence of the various stages of basophilic granulocy-
tic development that Ehrlich described. Beyond that, a 
number of considerations justify further study. Does the 
basophilic conversion of CGL alter the prognosis of the 
disease? Is basophilic conversion a form of "-blast" crisis? 
Does basophilic conversion require achange in therapy? Is 
there an acute basophilic leukemia as well as a basophilic 
conversion of CGL? Finally, does basophilic leukemia differ 
from tissue mast cell leukemia? 
Let us consider the last problem first. In spite of Ehrlich's 
clear distinction between the "tissue mast cel l " with its 
round, lymphocyte-like nucleus and huge cell body (15 to 
30/Am in diameter) and the small basophilic granulocyte of 
the blood and its marrow precursors, the two cell lines 
were often lumped together for many years. The fact that 
both cells contain similar functional constituents (his-
tamine, heparin and a potent chymase, and serotonin in 
animals) enhanced this tendency. But, properly, they 
should be separated into dual tissue and blood-borne roles, 
just as we recognize both tissue macrophages and those 
arisingfrom migrated mononuclears from the blood. In the 
basophilic granulocytic leukemias, distinction from sys-
temic mastocytosis and its leukemic counterpart, tissue 
mast cell leukemia, was never a problem because of the 
excellent distinction Efrati and his colleagues made in their 
original description of the tissue mast cell diseases. Al-
though tissue mast cell leukemia (Fig. 6) is rarely confused 
with the basophilic variant of CGL, it is confused, sur-
prisingly enough, with the more common promyelocytic or 
progranulocytic variant of acute granulocytic leukemia 
marked by the coarse and numerous azurophil granules 
(first set lysosomes) in the cytoplasm of the progran ulocytes 
and promyelocytes. The excessive bleeding that may be a 
symptom in both tissue mast cell leukemia (on the basis of 
focal hyperheparinemia) and in the promyelocytic leuke-
mic syndrome (on the basis of gran uie-ind ueed consump-
tive coagulopathy) often confuses the distinction. Fur-
thermore, the high heparin content o f the leukemic tissue 
mast cell may lead to needle-like, crystalline precipitates 
which are then mistaken as "Auer" rods. Another point of 
confusion is the conversion of the small, round, lympho-
cyte-like nuclear chromatin pattem of the normal tissue 
mast cell to the blast-like, finely stippled, chromatin pattern 
of the leukemic tissue mast cell. 
All ofthis confusion could be settled easily, inexpensively, 
and promptly by applying toluidine blue staining with 
a lcohol ic f ixat ion of the marrow or peripheral blood 
smears to be questioned (Figs. 5 and 7). Modern cytoche-
mists agree with our earlier observations that alcoholic 
toluidine blue induces a metachromatic (purple) staining of 
both tissue mast cell and basophilic granulocytic granules 
but does not do so to the azurophilic granules of the 
progran ulocytes and neutrophilic promyelocytes with 
which they may be confused in Romanowski stains. How-
ever, the skilled morphologists (and here we must include 
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the many hematology specialists among our medical tech-
nologists) have an even simpler way of distinguishing be-
tween metachromatic granules and the azurophi l ic 
lysosomes in ordinary blood or marrow smears. Since the 
high water content of the Romanowski stains dissolves the 
metachromatic granular contents in a helpful but haphaz-
ard fashion, the metachromatic granules wil l vary from 
solid purple to those which are washed out centrally or 
peripherally with a smudge of pink remaining in their 
centers or surrounding the granules, to those granules in 
which the contents are completely dissolved away, with 
their former sites marked by an empty cytoplasmic vac-
uole. In contrast, because the azurophilic granules are a 
hardy lot, they retain their uniform purple stain even in 
their damaged presentations in the smear. 
Next, is there an acute basophilic granulocytic leukemia 
either arising de novo or as a so-called "-blast" crisis of 
CGL? Hule (11) reported two cases of acute granulocytic 
leukemia with predominant basophilic granulocytes and 
Peralta and his associates (12), in the Cuban literature, 
confirmed the existence of acute basophilic leukemia. In 
these cases, two problems arise. First, unfamiliarity with the 
morphology of basophilic promyelocytes may lead to their 
misdiagnosis as progranulocytes or neutrophilic prom-
yelocytes. Second, failure to employ an alcoholic toluidine 
blue staining procedure to weed out the acute basophilic 
granulocytic leukemias from what appears to be an acute 
myeloblastic leukemia in Romanowki stains appears the 
most valid criticism o f the French American British (FAB) 
classification of the acute leukemias. The few cases of 
acute basophilic leukemia 1 have studied did not respond 
to therapy considered appropriate for AGL and had an 
unremitting course. Further study wi l l eventually determine 
if acute basophilic leukemias should have the same grave 
prognoses as the acute T-lymphoblastic and B-immu-
noblastic leukemias currently in the acute lymphocytic 
leukemia series. 
Lest anyone think these remarks are too provincial, at the 
International Congress of Hematology in Brazil in 1972 the 
Italian workers (13) reported 37 cases of acute basophilic 
leukemia in a 15-year period at the Cardarelli Hospital in 
Naples. Quattrin stated: "The scant number of reported 
cases of acute basophilic leukemia does not correspond to 
reality, the main reasons being: (a) the non-performance of 
the specific toluidine blue or Astra blau stains, on account 
of which many cases of acute granular leukemia are classi-
fied as common myeloblastic leukemia; (b) the very fast 
fatal course of the disease." He felt that a great many cases 
attributed to acute promyelocytic leukemia belonged in-
stead to acute basophilic leukemia. According to Quattrin, 
it is important in diagnosing these cases to distinguish 
between normal fibrinogen levels in the basophilic leuke-
mias and significantly depressed levels in the acute prom-
yelocytic syndrome. 
Another question we raised earlier concerns a change in 
the prognosis of CGL if the transformation to basophilic 
leukemia is established. In general, the answer is that the 
prognosis is worse than average. Gunz and Baikie (1) in 
their exhaustive leukemia text speculate that the reason 
may be that it is often detected at what they term "the stage 
of (leukemic) metamorphosis." Thus, the transformation to 
basophilic leukemia encountered in this study should also 
be included in the -blast crises described for CGL. The one 
known except ion to this general izat ion is ci ted by 
Wintrobe in the latest edition of his text (14). He described 
a patient with 80.0 x 10'/L basophils who received bus-
ulfan therapy and lived 87 months after the diagnosis had 
been made. Wintrobe's patient brings us to the final ques-
tion we asked: Should there be a change in therapy for 
patients such as the one we are studying? As in all chem-
otherapeutic trials, the appropriate answers cannot be 
given until the existence of this change in chronic gran-
ulocytic leukemia is widely recognized. 
To understand better the possibly pathophysiological con-
sequences of neoplasia of this series, we should know 
some of the more important properties and functions ofthe 
basophilic granulocyte (15): 
1. Locomotion 
2. Chemotaxis (16) 
a. Lymphocyte dependent 
b. Lymphocyte independent 
3. Phagocytosis 
a. For RBC 
b. As host LE cell 
4. IgE receptors (appropriate allergen leads to de-
granulation and/or disruption ofthe entire basophil, 
when complexed to IgE.) 
5. Heparin content in granules (metachromatic acid 
mucopolysaccharide) 
a. May lead to local hemorrhage due to heparin 
excess 
b. Stimulates fibroblasts to increased collagen for-
mation (fibrosis) 
6. Chymase content (may lead to local tissue necrosis) 
7. Histamine content (complement-induced release) 
8. Serotonin content in laboratory animal basophils 
(not proved for human basophils) 
9. Basophil hypersensitivity reaction (as in ulcerative 
colitis, Hunner's ulcer, penicillin sensitivity, histo-
incompatibility, etc) 
10. Platelet-activating factor derived from IgE sensitized 
basophils causing platelet function 
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11. Kallikrein-like activity (compensatory basophilic 
migration in lesions of patients with Fitzgerald fac-
tor deficiency) 
Pertinent to a study of this basophilic cell line is the recent 
report by Juhlin and his colleagues (17) of the case of a 
52-year-old patient who , instead of having too many 
basophils, constantly lacked both eosinophil and baso-
philic granulocytes. The patient suffered from repeated 
infections, asthma, and hemolytic anemia. Juhlin et al 
argued that the lack was due to immunologic destruction of 
the missing cells. Because of the combined defect with its 
immunologic etiology, we still do not know what life would 
be like without basophils alone, but their case affords 
important clues. 
Many years ago, Henry Rappaport reported that the in-
creased reticulin deposition and fibrosis o f the bone mar-
row in chronic granulocytic leukemia were in direct pro-
portion to the absolute basophilic granulocyte count of the 
marrow. Significantly, the marrow of our patient showed 
pronounced fibrosis at the time of the "basophilic gran-
ulocytic crisis," a fibrosis which became more severe as 
death approached. Another reason for embarrassment of 
the microcirculation of the marrow leading to marrow 
fibrosis is that as greatly increased numbers of mega-
karyocytes become activated, a cocoon of fibrin (then 
reticulin) forms around those that have broken out into 
marrow sinuses, resulting in the classic "entrapped mega-
karyocytes" of the myeloproliferative disorders. Further-
more, I believe that any marked hyperplasia of cellular 
elements of any type in the confined marrow cavity leads 
to some impingement upon the thin-walled marrow sinus 
microcirculation, with the same resulting fibrosis. Ob-
viously, all these mechanisms were present and potentially 
operative in our patient. The presence of the Philadelphia 
chromosome and zero LAP score in this patient on his 
initial admission in December 1975, along with the origi-
nal, extremely high white count, confirmed the basic diag-
nosis of chronic granulocytic leukemia. Fibrosis of the 
marrow has occasionally been reported in CGL and is 
being reported more and more frequently as another grave 
prognostic sign in this disease. 
The remainder of the patient's course was as follows. After 
a third course of Rubidazone therapy, which initially re-
duced his peripheral white count, his white cell and plate-
let counts began to rise again in late August without 
significant reduction in the tumor in his liver and spleen. 
Hydroxyurea therapy was started, but his leukocytes con-
tinued to climb to 180,000 cu mm with 28% mature and 
immature basophils persisting and an increase in my-
eloblasts to 21 % ofthe total leukocytes. Death was due to a 
rapdily developing E. coli pneumonia, as Dr. Nixon indi-
cated, on October 4, 1977, approximately 22 months after 
CGL had been diagnosed. Important findings in the pa-
tient's last marrow report were 32.2% myeloblasts, 1 7.0% 
immature basophils, and 18.6% mature basophilic gran-
ulocytes. Extensive leukemic infiltration was found in the 
liver (3,190 gm) and spleen (1,960 gm), as well as in the 
mesenteric and para-aortic nodes and kidneys. Terminally, 
the marrow showed 90-100% infiltration of both the my-
eloblasts and the basophilic granulocytes that had marked 
his later course, combined with extensive fibrosis, as pre-
viously noted. 
Dr. Van Slyck: 
As part of a CGL treatment protocol, those of us involved in 
Southwest Oncology Group (SWOG) investigations looked 
atthe fibrosis in marrows before, during, and after myleran 
therapy, with the idea of trying to obtain useful information 
on this issue. The study took ten years to complete because 
of very slow case accrual, and the results were inconclu-
sive. Many ofthe 100 patients in the study clearly had some 
fibrosis in their marrows before they were ever treated. The 
disease itself, as Dr. Rebuck stressed, was associated with 
an increase in marrow fibrosis as time passed, but how 
much of a contribution myleran therapy made to the 
process is speculative. We all suspect that it does some-
thing to accelerate fibrosis, but individual cases differ. 
Thus, we have no clear causal relationship concerning the 
marrow fibrosis in today's case. So, in summary, we believe 
that myleran can enhance marrow fibrosis, but the fibrosis 
can also proceed without myleran. 
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Fig. 4 
Basophilic Leukemia Complicating Chronic Granulocytic Leukemia 
This photomicrograph represents the patient's blood and marrow picture in June 1977 (mature basophils in the blood 26%; immature basophils 15.5%). 
The three central cells are mature basophilic granuk>cytes. This picture should be compared w i th the morphology of the tissue mast cells in Fig. 6. 
Leishman's stain ( x 1700). 
Fig. 5 
Deeper Leishman staining on the left (ordinary Romanowski blood staining) of the basophilic promyelocytes contrasted w i th the identifying paler but 
definitely metachromatically positive basophilic promyelocyte counterpart in the alcoholic toluidine blue stain on the right. Such metachromatic 
identif ication is essential to avoid misinterpretation of the basophilic promyelocyte in ordinary blood stains as a "heavy granular promyelocyte" of the 
neutrophilic series ( x 1700). 
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Fig. 6 
Tissue Mast Cell Leukemia 
Representative field from the blood or marrow of a patient with tissue mast cell leukemia so that the morphology of the leukemic tissue mast cells can be 
compared with the structure of the leukemic basophilic granulocytes in Figs. 4 and 5. Note the larger cytoplasmic-to-nuclear ratk) in tissue mast cells, 
and the tear-drop secretion of heparin at the edge. Like basophil granules, tissue mast cell granules contain heparin and are truly metachromatic 
Leishman's stain (x 1700). 
r 
Fig. 7 
Alcoholic toluidine blue staining of leukemic tissue mast cells from the same patient depicted in Fig. 6. Note the metachromatic (purple) staining of the 
granules. The large cell body of the leukemic mast cells can be appreciated here when contrasted with the smaller cytoplasmic rim presented by the 
basophilic promyelocytes of Fig. 5. Tissue mast cell leukemia is another leukemia that can be misinterpreted as "promyelocyte" leukemia when 
metachromatic staining is not employed. Alcoholic tolukline blue stain (x 1700). 
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